Nasdaq · Healthcare
SPRUCE BIOSCIENCES, INC. (SPRB)
As-reported financials and recent SEC filings for SPRUCE BIOSCIENCES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-39.0M
Net margin
—
Diluted EPS
$-50.83
ROE
-91.7%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | $0 | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-36.5M | $-56.2M | $-52.0M | $-47.3M | $-42.1M |
| Net income | $-39.0M | $-53.0M | $-47.9M | $-46.2M | $-42.3M |
| Diluted EPS | $-50.83 | $-96.40 | $-86.80 | $-137.20 | $-126.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →8-K2026-05-26
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →Largest Healthcare peers
Go deeper on SPRB
Search SPRUCE BIOSCIENCES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.